$11.30
1.62% day before yesterday
Nasdaq, Sep 26, 10:00 pm CET
ISIN
US21900C3088
Symbol
CRMD

CorMedix Inc Target price 2025 - Analyst rating & recommendation

CorMedix Inc Classifications & Recommendation:

Buy
85%
Hold
15%

CorMedix Inc Price Target

Target Price $20.40
Price $11.30
Potential
Number of Estimates 8
8 Analysts have issued a price target CorMedix Inc 2026 . The average CorMedix Inc target price is $20.40. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 13 analysts: 11 Analysts recommend CorMedix Inc to buy, 2 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the CorMedix Inc stock has an average upside potential 2026 of . Most analysts recommend the CorMedix Inc stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 43.47 237.57
446.51%
EBITDA Margin -50.72% 59.87%
218.03%
Net Margin -41.25% 50.86%
223.31%

9 Analysts have issued a sales forecast CorMedix Inc 2025 . The average CorMedix Inc sales estimate is

$238m
Unlock
. This is
95.56% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$268m 120.75%
Unlock
, the lowest is
$191m 57.31%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $43.5m
2025
$238m 446.51%
Unlock
2026
$380m 59.96%
Unlock
2027
$403m 5.99%
Unlock
2028
$409m 1.45%
Unlock
2029
$408m 0.17%
Unlock
2030
$446m 9.25%
Unlock
2031
$437m 2.05%
Unlock
2032
$465m 6.40%
Unlock

3 Analysts have issued an CorMedix Inc EBITDA forecast 2025. The average CorMedix Inc EBITDA estimate is

$142m
Unlock
. This is
185.34% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$146m 193.74%
Unlock
, the lowest is
$137m 174.16%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-22.1m 54.90%
2025
$142m 745.08%
Unlock
2026
$221m 55.58%
Unlock

EBITDA Margin

2024 -50.72%
2025
59.87% 218.03%
Unlock
2026
58.23% 2.74%
Unlock

9 CorMedix Inc Analysts have issued a net profit forecast 2025. The average CorMedix Inc net profit estimate is

$121m
Unlock
. This is
136.16% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$160m 213.49%
Unlock
, the lowest is
$97.3m 90.11%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-17.9m 61.31%
2025
$121m 773.84%
Unlock
2026
$175m 45.02%
Unlock
2027
$190m 8.42%
Unlock
2028
$185m 2.77%
Unlock
2029
$176m 4.94%
Unlock
2030
$197m 12.28%
Unlock
2031
$122m 38.22%
Unlock
2032
$126m 3.13%
Unlock

Net Margin

2024 -41.25%
2025
50.86% 223.31%
Unlock
2026
46.11% 9.34%
Unlock
2027
47.16% 2.28%
Unlock
2028
45.20% 4.16%
Unlock
2029
43.04% 4.78%
Unlock
2030
44.23% 2.76%
Unlock
2031
27.89% 36.94%
Unlock
2032
27.03% 3.08%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -0.30 1.62
67.03% 640.00%
P/E 6.98
EV/Sales 2.91

9 Analysts have issued a CorMedix Inc forecast for earnings per share. The average CorMedix Inc EPS is

$1.62
Unlock
. This is
128.17% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$2.15 202.82%
Unlock
, the lowest is
$1.30 83.10%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-0.30 67.03%
2025
$1.62 640.00%
Unlock
2026
$2.35 45.06%
Unlock
2027
$2.55 8.51%
Unlock
2028
$2.48 2.75%
Unlock
2029
$2.35 5.24%
Unlock
2030
$2.64 12.34%
Unlock
2031
$1.63 38.26%
Unlock
2032
$1.68 3.07%
Unlock

P/E ratio

Current 15.92 298.41%
2025
6.98 56.14%
Unlock
2026
4.81 31.09%
Unlock
2027
4.44 7.69%
Unlock
2028
4.57 2.93%
Unlock
2029
4.80 5.03%
Unlock
2030
4.28 10.83%
Unlock
2031
6.92 61.68%
Unlock
2032
6.71 3.03%
Unlock

Based on analysts' sales estimates for 2025, the CorMedix Inc stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 5.69 98.74%
2025
2.91 48.86%
Unlock
2026
1.82 37.49%
Unlock
2027
1.72 5.65%
Unlock
2028
1.69 1.43%
Unlock
2029
1.69 0.17%
Unlock
2030
1.55 8.47%
Unlock
2031
1.58 2.09%
Unlock
2032
1.49 6.02%
Unlock

P/S ratio

Current 7.26 98.57%
2025
3.71 48.87%
Unlock
2026
2.32 37.48%
Unlock
2027
2.19 5.66%
Unlock
2028
2.16 1.43%
Unlock
2029
2.16 0.17%
Unlock
2030
1.98 8.47%
Unlock
2031
2.02 2.09%
Unlock
2032
1.90 6.02%
Unlock

Current CorMedix Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
JMP Securities
Locked
Locked
Locked Sep 09 2025
HC Wainwright & Co.
Locked
Locked
Locked Aug 08 2025
HC Wainwright & Co.
Locked
Locked
Locked Jun 30 2025
D. Boral Capital
Locked
Locked
Locked Jun 30 2025
Needham
Locked
Locked
Locked Jun 24 2025
D. Boral Capital
Locked
Locked
Locked Jun 23 2025
RBC Capital
Locked
Locked
Locked Jun 20 2025
Analyst Rating Date
Locked
JMP Securities:
Locked
Locked
Sep 09 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Aug 08 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Jun 30 2025
Locked
D. Boral Capital:
Locked
Locked
Jun 30 2025
Locked
Needham:
Locked
Locked
Jun 24 2025
Locked
D. Boral Capital:
Locked
Locked
Jun 23 2025
Locked
RBC Capital:
Locked
Locked
Jun 20 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today